RITUXIMAB BIOSIMILAR RTXM83 POST-MARKETING SURVEILLANCE IN BRAZIL: EVALUATION OF THE ADVERSE EVENTS SPONTANEOUSLY REPORTED TO PHARMACOVIGILANCE
Background: Biosimilars are highly similar to their reference products, but unlike generic drugs, they are not identical. Differences between a biosimilar and its reference product may arise because of the complexity of biologics, differences in the cell lines and processes used during manufacturing...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-10-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137921003205 |